By Adriano Marchese

Certara's stock rose in premarket trading Monday after it reiterated guidance for the year and said it would look to buy back up to $100 million of its public float.

Shares traded nearly 11% higher in ahead of the morning bell at $14.32.

The drug development company said that it continues to expect revenue to come in between $415 million and $425 million in 2025, with adjusted earnings in the range of 42 cents to 46 cents.

Full-year adjusted earnings before interest, taxes, depreciation and amortization margin is still expected to be between 30% and 32%.

Certara also said that its board has authorized a share repurchase program to buy back up to $100 million of its stock for cancellation.

Shares have performed strongly so far in the year, rising 21% to close on Friday at $12.91. In the past 52 weeks however, the stock is down 27%.

At that closing price, the company would be on track to buy about 7.7 million shares with its budget of $100 million.

Chief Executive William Feehery said the buyback reflects continued confidence in the company's strategy and the investments it is making using AI across the Certara platform.

"We are encouraged by the robust interest in our solutions from customers and are focused on executing our 2025 commercial and R&D goals," Feehery said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

April 14, 2025 08:38 ET (12:38 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.